

ERRATUM

Study on the price of orphan drugs

Phase I: Overview of the conditions for marketing orphan drugs in Europe

Paragraph and page number	Former text	New text
II.4, map 2, p18	180 000 € (AU), 140-150 000€ (DK, GE), 130-139 000€ (NL), 120-129 000€ (FI, FR, IR), 108-115 000€ (ES, PO, SW, UK)	150 000€ (AU), 110-125 000 (DK, GE, NL), 99-109 000€ (FI, FR, IR, 88-95 000€ (ES, PO, SW, UK)
V.4.1.1, figure 1, p36	Carbaglu: 300 000	Carbaglu: 130 000
V.4.1.2, p36 line 14	“10 to 20 times less expensive”	“5 to 20 times less expensive”
V.4.2, p36 line 1	“is about 3 times higher”	“is 2 to 3 times higher”